NCT03959501View on ClinicalTrials.gov

Metabolic Responses of Dapagliflozin vs Sitagliptin in T2DM Patients Inadequately Controlled With Insulin Therapy

PHASE4CompletedINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

August 16, 2017

Primary Completion Date

October 16, 2020

Study Completion Date

October 16, 2020

Conditions
Type 2 DiabetesKetonemia
Interventions
DRUG

Dapagliflozin 10 mg

Dapagliflozin 10mg daily for 24 weeks

DRUG

Sitagliptin 100mg

Sitagliptin 100mg daily for 24 weeks

Trial Locations (1)

Unknown

L2 Diabetes Centre, Queen Mary Hospital, Hong Kong

All Listed Sponsors
lead

The University of Hong Kong

OTHER

NCT03959501 - Metabolic Responses of Dapagliflozin vs Sitagliptin in T2DM Patients Inadequately Controlled With Insulin Therapy | Biotech Hunter | Biotech Hunter